Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

OMT strategy

Phase 3Small molecule

BBeijing Anzhen Hospital

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Coronary Arterial Disease (CAD)Recruiting

Coronary Arterial Disease (CAD)Phase 3

Recruiting

Timeline

Expected Milestones

Q3 2027

ApprovedRecruiting

Coronary Arterial Disease (CAD)

NCT06855537

Clinical

Trials by Indication[1]

Coronary Arterial Disease (CAD)1 trial

Randomized Controlled Study on the Effectiveness of Interventional Therapy for Non-Flow-Limiting Vulnerable Plaques

Recruiting·BBeijing Anzhen Hospital·Approved·NCT06855537·2,190 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for OMT strategy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — OMT strategy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for OMT strategy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Beijing Anzhen Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: BBeijing Anzhen Hospital

Related News